Source comparison
MOTS-c Dosage Exercise Mimetic 2026: Comparison by Protocol Type
Standard Research Protocol 5–10mg Twice weekly AMPK activation, insulin sensitivity improvement, mitochondrial biogenesis Fasted morning or 60–90 min pre-training Gold standard for metabolic research. Reproducible, well-tolerated, sufficient for measurable sub
This comparison does not assign a generated winner or score.
- Standard Research Protocol
- 5–10mg
- Twice weekly
- AMPK activation, insulin sensitivity improvement, mitochondrial biogenesis
- Fasted morning or 60–90 min pre-training
- Gold standard for metabolic research. Reproducible, well-tolerated, sufficient for measurable substrate switching in most populations
- Performance Enhancement Protocol
- 10–12mg
- Enhanced glucose disposal during training, improved lactate threshold, substrate flexibility
- 60–90 min before resistance or endurance sessions
- Higher dose justified only when paired with structured training stimulus. Monotherapy at this range shows marginal benefit over 10mg
- Therapeutic Protocol (Insulin Resistance)
- 5–8mg
- Twice weekly, titrated slowly
- Fasting glucose reduction, postprandial insulin normalisation, HbA1c lowering
- Fasted morning administration preferred
- Lower starting dose reduces GI side effects in metabolically compromised populations; efficacy comparable to higher doses when baseline dysfunction is severe
- Maintenance Protocol (Post-Intervention)
- 5mg
- Once weekly
- Sustained mitochondrial function, prevention of metabolic regression
- Flexible. Morning or pre-training
- Minimal effective dose for maintaining gains after an 8–12 week loading phase; used in long-term metabolic health studies
- This comparison reflects the protocols used in peer-reviewed research as of 2026. Dosing above 12mg per injection is not supported by published safety or efficacy data.